|
Population-Based Modeling of Cholesterol Lowering in the United States Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Population-Based Modeling of Cholesterol Lowering in the United States conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Population-Based Modeling of Cholesterol Lowering in the United States Clinical research trials and Population-Based Modeling of Cholesterol Lowering in the United States healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Population-Based Modeling of Cholesterol Lowering in the United States. Population-Based Modeling of Cholesterol Lowering in the United States Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Population-Based Modeling of Cholesterol Lowering in the United States clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Population-Based Modeling of Cholesterol Lowering in the United States condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Population-Based Modeling of Cholesterol Lowering in the United States  Population-Based Modeling of Cholesterol Lowering in the United States
Population-Based Modeling of Cholesterol Lowering in the United States
For Condition: Coronary Disease,Cardiovascular Diseases,Heart Diseases,Hypercholesterolemia,Coronary Heart Disease Risk Reduction
Status: Completed
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To evaluate the cost-effectiveness of cholesterol-lowering strategies in the United States population. The study used the Coronary Heart Disease (CHD) Policy Model, a state-transition computer simulation model used to obtain forecasts of the public health impact and economic cost of CHD in the United States population.
Details: BACKGROUND: The study was part of an Institute-initiated Request for Applications (RFA) titled "Cost-Effective Strategies of Cholesterol-Lowering" released by the NHLBI in 1990. The RFA was stimulated by the controversy concerning costs and cost-effectiveness that followed the 1987 report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The RFA was intended to support a broad and thorough quantitative exploration of the potential health benefits and costs of cholesterol-lowering from multiple perspectives. DESIGN NARRATIVE: The study added to the CHD Policy Model the capability to model the consequences of reductions in LDL cholesterol and increases in HDL/LDL ratios in the United States population. The CHD Policy Model was used for several studies, including: to compare the implications of using alternative epidemiologic studies as the basis for estimating the association between cholesterol levels and CHD risk; to derive cutting points for initiating cholesterol reduction, specific to age, sex, and CHD risk factors, and based on cost-effectiveness criteria; to compare the cost-effectiveness of specific targeted and population-wide strategies for cholesterol reduction; to incorporate the effects of treatments on quality of life, including both adverse effects of cholesterol-lowering drugs and reductions in CHD morbid events; and finally, to perform a cost-effectiveness analysis of cholesterol screening, incorporating costs of screening, effects of measurement error on misclassification of patients, and variations in individual cholesterol levels over time.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Male
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: 4907;
Study Start Date: August 1991
Record last reviewed: September 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005463
Other Coronary Heart Disease Risk Reduction Studies:
1. Evaluation of Low Literacy CVD Nutrition Education
2. Self-Scored Cardiovascular Disease Risk Appraisal
3. Providers for Smoking Prevention Programs
4. Fat Reduction Intervention Trial in African-Americans
5. Trial of Smoking Cessation Programs in Black Churches
Related Studies:
Other Coronary Heart Disease Risk Reduction Clinical Trials
Other Clinical Trials
Other Clinical Trials
Population-Based Modeling of Cholesterol Lowering in the United States
|
|
|
|
|
|
|
|
